Dr. Stephan Stilgenbauer, an expert in chronic lymphocytic leukaemia (CLL) from Ulm, Germany, discusses the new age of care for a wide range of CLL patients. He defines ‘ultra high-risk CLL’, which is associated with a poor prognosis and represents a great clinical challenge. Newer agents are hoped to overcome shortcomings of chemotherapy. For example, the phase III RESONATE trial showed that ibrutinib therapy in CLL provided significant benefits compared to standard ofatumumab therapy. Like other cancer types, delivery of agents in a combination approach is recommended to promote patient outcomes in CLL.
Supported by an educational grant from Gilead Sciences Europe through Patient Empowerment Network
View more programs featuring
Prof Stephan Stilgenbauer